{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:57:47Z","timestamp":1778914667193,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3130,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1093\/annonc\/mdq607","type":"journal-article","created":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T02:30:15Z","timestamp":1290479415000},"page":"1011-1018","source":"Crossref","is-referenced-by-count":29,"title":["Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?"],"prefix":"10.1016","volume":"22","author":[{"given":"S.","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq607_bb0010","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html (January 2010, date last accessed)"},{"key":"10.1093\/annonc\/mdq607_bb0015","unstructured":"R Peto. The Early Breast Cancer Trialists\u2019 Collaborative Group. The worldwide overview: new results for the systemic adjuvant therapies. In San Antonio Breast Cancer Symposium, San Antonio, TX 2007"},{"key":"10.1093\/annonc\/mdq607_bb0020","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.3747\/co.2008.173","article-title":"Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer","volume":"15","author":"Towns","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq607_bb0030","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2007.14.8742","article-title":"Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?","volume":"26","author":"Ewer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0035","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0040","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0045","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq607_bb0050","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0055","first-page":"3722","article-title":"Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy","volume":"46","author":"Torti","year":"1986","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdq607_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005006.pub3","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdq607_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq607_bb0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mdq607_bb0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq607_bb0085","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.drudis.2008.05.011","article-title":"Cardiotoxicity of the new cancer therapeutics\u2014mechanisms of, and approaches to, the problem","volume":"13","author":"Force","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1093\/annonc\/mdq607_bb0090","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0095","unstructured":"http:\/\/www.roche.com\/investors\/ir_update\/inv-update-2009-12-14b.htm (February 2010, date last accessed)"},{"key":"10.1093\/annonc\/mdq607_bb0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(09)70042-7","article-title":"Cardiovascular toxicity caused by cancer treatment: strategies for early detection","volume":"10","author":"Altena","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","article-title":"Cardiac toxicity in breast cancer survivors: review of potential cardiac problems","volume":"14","author":"Bird","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq607_bb0110","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1200\/JCO.2010.30.6274","article-title":"Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline\u2013trastuzumab interaction","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003917.pub3","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdq607_bb0120","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0130","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1093\/annonc\/mdq607_bb0135","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","article-title":"Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart","volume":"44","author":"de Nigris","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdq607_bb0140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2009.25.2544","article-title":"Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program","volume":"28","author":"de Gramont","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq607_bb0145","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/5\/1011\/431021\/mdq607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:23:33Z","timestamp":1624699413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419385357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0923753419385357"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq607","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}